Leveraging SARS-CoV-2 Main Protease (M
COVID-19
SARS-CoV-2
coronavirus
hydrolysis
inhibitor
main protease
solubility
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
12 Jan 2024
12 Jan 2024
Historique:
received:
07
12
2023
revised:
05
01
2024
accepted:
09
01
2024
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
The implementation of innovative approaches is crucial in an ongoing endeavor to mitigate the impact of COVID-19 pandemic. The present study examines the strategic application of the SARS-CoV-2 Main Protease (M
Identifiants
pubmed: 38256046
pii: ijms25020971
doi: 10.3390/ijms25020971
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian National Research Council (CNR)
ID : Grant COVPI- Tackling coronaviruses-related diseases by developing viral Protease Inhibitors